Product Name: Human PCSK9 Antibody (Evolocumab, Research Use)
Catalog Number: NBR-0619
Target Name: PCSK9
Trade Name: Evolocumab
Antibody Drug Description: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: PCSK9
Synonyms: NARC-1; FH3; HCHOLA3
Target Description: PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a Protein Coding gene. Diseases associated with PCSK9 include Hypercholesterolemia, Familial, 3 and Homozygous Familial Hypercholesterolemia. Among its related pathways are Plasma lipoprotein assembly, remodeling, and clearance and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). Gene Ontology (GO) annotations related to this gene include RNA binding and protein self-association. An important paralog of this gene is TPP2
Ensembl: ENSG00000169174
Uniprot: Q8NBP7